NIH AIDS Reagent Program
20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	Env-20 (85-102)
Catalog Number:	1462
Lot Number:	6/4/92
Provided:	100 µg, 1.0 mg/ml
Description:	Residues 85-102 from HTLV-II gp46.
Sequence:	KKPNRQGLGYYSPSYNDP
HPLC Purity:	Purity >90% by reverse phase HPLC. Amino acid sequence analysis was used to confirm peptide sequence.
Synthesis:	Synthesized by FMOC chemistry
Solubility:	Dilutions should be made in 10 mM carbonate buffer, pH 9.6 (Sigma, Catalog #C3041).
Special Characteristics:	Env-20 represents the N-terminal of HTLV-II gp46 and reacts with 83% of all HTLV-II and 8% of HTLV-I serum samples tested. Has been combined with Env-2 in a peptide "cocktail" assay to successfully distinguish between HTLV-I and HTLV-II antibodies. Dilutions should be made in 10 mM carbonate buffer, pH 9.6 (Sigma, Catalog #C3041). Protocol: ELISA for Detection of HTLV-I and HTLV-II Positive Sera
Recommended Storage:	-70°C.
Contributor:	Dr. Renu B. Lal

References:

Lal RB, Griffis KP. Predictive B- and T-cell linear epitopes in structural proteins of HTLV-I, HLTV-II, and STLV-I. *AIDS Res Hum Retroviruses* **7**:663-670, 1991.

Lal RB, Rudolph DL, Kaplan JE, Hjelle B, Levine PH, Coligan JE, Viscidi RP. Identification of immunodominant epitopes in envelope glycoprotein of human T lymphotropic virus type II. *Virology* **186**:274-279, 1992.

Rudolph DL, Lal RB. Discrimination of human T-lymphotropic virus type-I and type-II infections by synthetic peptides representing structural epitopes from the envelope glycoproteins. *Clin Chem* **39**:288-292, 1993.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Env-20$^{85-102}$ from Dr. Renu Lal (cat# 1462)." Also include the references cited above in any publications.

A US Government Patent (#5738805) has been issued on this research material. Scientists at for-profit institutions or who intend commercial use of this reagent must contact Ms. Lisa Blake-DiSpigna at email address LBlake-DiSpigna@cdc.gov and specify in the email the name of the reagent, and a description of the intended use of the reagent.

Last Updated: July 31, 2018